EMEtsuko Miyagi

Etsuko Miyagi

*This is an algorithmically generated author record based on publicly available information.

Etsuko Miyagi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Fumiki Hirahara

    Departments of Obstetrics and Gynecology and

    2 shared publications
  • Akiko Sukegawa

    Department of Obstetrics and Gynecology, Yokohama City University School of Medicine, Kanagawa, Japan

    1 shared publication
  • Atsushi Kamijyo

    Psychiatry, Yokohama City University School of Medicine

    1 shared publication
  • Atsushi Morita

    International Graduate School of Arts and Sciences, Yokohama City University, Yokohama, Japan

    1 shared publication
  • Haruya Saji

    Departments of Obstetrics and Gynecology and

    1 shared publication
  • Hidetaro Yasumitsu

    International Graduate School of Arts and Sciences, Yokohama City University, Yokohama, Japan

    1 shared publication

Latest Publications

  • Anxiety and prevalence of psychiatric disorders among patients awaiting surgery for suspected ovarian cancer

    by Akiko Sukegawa, Etsuko Miyagi, Mikiko Asai‐Sato, Haruya Saji, Ken Sugiura, Takehiko Matsumura, Atsushi Kamijyo, Yoshio Hirayasu, Naoyuki Okamoto, Fumiki Hirahara

    Aim:  The goal of the current study was to determine the anxiety level and prevalence of psychiatric disorders among patients awaiting surgery for ovarian tumors. Also analyzed were the predictive factors for psychiatric disorders and changes after surgical diagnosis.Methods:  Patients who underwent surgery for ovarian tumors were examined before and after surgery with the MINI International Neuropsychiatric Interview, the Spielberger State‐Trait Anxiety Inventory (STAI) and the Mausley Personality Inventory (MPI). Participants diagnosed with cancer were examined a third time after being given an explanation about whether or not adjuvant chemotherapy was required.Results:  Twenty‐seven participants completed the study and were analyzed. Nine (33.3%) of these 27 participants were diagnosed as having adjustment disorder. There were no differences in the demographic data, STAI trait anxiety score and MPI score between the participants with or without adjustment disorder. At the pre‐surgical interview, the STAI state anxiety score of the participants was high (49.5 ± 10.30). After pathological examination of the tumors, it was found that 12 patients had cancer (malignant group) and 15 patients had a benign tumor (benign group). At pre‐surgery, the prevalence of adjustment disorder and the level of anxiety in the benign group were similar to those in the malignant group. There was a second surge of anxiety in patients who needed chemotherapy.Conclusion:  The above findings demonstrate that patients with suspected ovarian cancer experience a high level of anxiety. Physicians should be aware of the risk of adjustment disorder in these patients. Additionally, ovarian cancer patients need psychological assessment during the course of treatment.


  • Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma

    by Atsushi Morita, Etsuko Miyagi, Hidetaro Yasumitsu, Hiroshi Kawasaki, Hisashi Hirano, Fumiki Hirahara

    Clear cell adenocarcinoma (CCA) has a highly malignant potential in human epithelial ovarian cancer. The serum CA‐125 is widely used as a marker for ovarian cancer, but the level is relatively low in CCA. Therefore, new sensitive biomarkers are required. In this report, we describe a promising proteomic analysis that is differentially expressed in CCA when compared to mucinous adenocarcinoma, using the ovarian cultured cell lines OVISE, OVTOKO, and MCAS. The disease‐associated proteins were identified by 2‐D differential gel electrophoresis (2‐D DIGE) and MS. In this analysis, 18 up‐regulated and 31 down‐regulated spots were observed that had at least two‐fold differences in the two CCA cell lines than in MCAS as control cells. Some of the proteins differentially expressed in CCA were previously observed as alternative expression levels in ovarian and/or other cancers in clinical samples. In a subsequent preliminary differential study using surgical specimens from patients with CCA, it was demonstrated that the identified proteins were expressed differentially in actual tissues, as well as in the CCA culture cells. The results from this investigation show the potentiality of a proteomic approach for identifying disease‐associated proteins, which may eventually serve as diagnostic markers or therapeutic targets in CCA.